The pharma industry has been facing increasing pressure in recent years to adopt eco-friendly practices without compromising product safety or efficacy.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh